Why an obesity trial with a missed weight-loss target still teaches us about health

Weight-loss programs often make the scale their main instrument. The SLIM-TARGET study deliberately compared different ambitions for weight reduction: at least 3% versus at least 7% at twelve months, using a more intensive program with additional nutrition and exercise support and some pharmacotherapy.

Among 294 randomized participants with obesity-related disorders, the intensive group lost an average 2.5% of body weight versus 1.7% in standard care. The trial did not find a significant advantage on its composite primary endpoint of weight loss plus improvement in at least two obesity-related disorders. Yet remission of health disorders was reported in 16.9% versus 6.2% (adjusted odds ratio 3.08, 95% CI 1.08–8.82), and the intensive group had a greater reduction in visceral fat area. Those are secondary outcomes, susceptible to multiplicity and chance.

The result illustrates why our metabolic-health dashboards should include blood pressure, functional ability, sleep, metabolic parameters and patient goals alongside weight. Weight change is an important intermediate measure; the disease and functional outcomes are the real point of treatment.

Clinical practice should not infer a universal optimal percentage of weight loss from this relatively modest between-arm separation, nor treat a secondary signal as proof that intensive intervention is superior.